Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2006
Bulevirtide for treating chronic hepatitis D (TA896)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 June 2023
Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Entecavir for the treatment of chronic hepatitis B (TA153)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 August 2008
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)Product type:GuidanceProgramme:Diagnostics guidancePublished: 7 June 2023
Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2018
Hepatitis B and C testing: people at risk of infection (PH43)Product type:GuidanceProgramme:Public health guidelineLast updated: 1 March 2013Published: 12 December 2012
Hepatitis B (chronic): diagnosis and management (CG165)Product type:GuidanceProgramme:Clinical guidelineLast updated: 20 October 2017Published: 26 June 2013
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 November 2013Published: 28 January 2004
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2015
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2015
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2010
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 November 2013Published: 23 August 2006
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Sofosbuvir for treating chronic hepatitis C (TA330)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2017
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 February 2018
Stent insertion for bleeding oesophageal varices (IPG392)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 April 2011
Telbivudine for the treatment of chronic hepatitis B (TA154)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 August 2008
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 March 2017
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2009
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)Product type:AdviceProgramme:Medtech innovation briefingPublished: 2 March 2015
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 17 January 2020Published: 23 September 2015